Kelly Baillie, of the NHS Greater Glasgow & Clyde, Glasgow, UK, presents the key findings from the Cancer Medicines Outcome Programme, a collaboration between NHS Greater Glasgow and Clyde and the University of Strathclyde with the aim of investigating whether medicines are as effective in real world populations, as they are in clinical trials. Looking specifically at men who received abiraterone and enzalutamide for the treatment of metastatic, castration-resistant prostate cancer, this initiative used electronic record linkage to combine the chemotherapy prescribing system with other useful patient information. At the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Baillie shares the results of this retrospective study.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Update from the Scottish Cancer Medicines Outcome Programme
